Biohaven Pharmaceutical Holding Co Ltd (BHVN) Forecasted to Post Q2 2019 Earnings of ($4.07) Per Share

Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) – Analysts at Svb Leerink dropped their Q2 2019 earnings estimates for Biohaven Pharmaceutical in a report released on Wednesday, May 8th. Svb Leerink analyst M. Goodman now anticipates that the company will earn ($4.07) per share for the quarter, down from their prior forecast of ($1.87). Svb Leerink currently has a “Outperform” rating and a $67.00 target price on the stock. Svb Leerink also issued estimates for Biohaven Pharmaceutical’s Q3 2019 earnings at ($1.60) EPS, Q4 2019 earnings at ($2.32) EPS and FY2019 earnings at ($9.40) EPS.

A number of other research firms also recently commented on BHVN. Zacks Investment Research raised shares of Biohaven Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Thursday, May 9th. Oppenheimer lifted their target price on shares of Biohaven Pharmaceutical from $54.00 to $70.00 and gave the stock an “outperform” rating in a research report on Monday, April 15th. Needham & Company LLC lifted their target price on shares of Biohaven Pharmaceutical to $70.00 and gave the stock a “buy” rating in a research report on Wednesday, May 8th. Piper Jaffray Companies lifted their target price on shares of Biohaven Pharmaceutical from $75.00 to $100.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 8th. Finally, Canaccord Genuity lifted their target price on shares of Biohaven Pharmaceutical from $46.00 to $89.00 and gave the stock a “buy” rating in a research report on Monday, April 15th. Three research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. Biohaven Pharmaceutical has a consensus rating of “Buy” and a consensus price target of $69.19.

NYSE:BHVN opened at $60.26 on Monday. Biohaven Pharmaceutical has a 12 month low of $26.96 and a 12 month high of $64.83. The company has a market capitalization of $2.78 billion, a price-to-earnings ratio of -9.80 and a beta of 0.60.

Biohaven Pharmaceutical (NYSE:BHVN) last posted its earnings results on Tuesday, May 7th. The company reported ($1.41) EPS for the quarter, topping analysts’ consensus estimates of ($1.50) by $0.09. During the same quarter in the prior year, the company posted ($2.32) earnings per share.

Institutional investors have recently modified their holdings of the company. Manchester Capital Management LLC purchased a new position in shares of Biohaven Pharmaceutical during the 1st quarter worth $52,000. Flinton Capital Management LLC purchased a new position in shares of Biohaven Pharmaceutical during the 4th quarter worth $42,000. Neuburgh Advisers LLC purchased a new position in shares of Biohaven Pharmaceutical during the 4th quarter worth $52,000. NumerixS Investment Technologies Inc boosted its stake in shares of Biohaven Pharmaceutical by 333.3% during the 1st quarter. NumerixS Investment Technologies Inc now owns 2,600 shares of the company’s stock worth $134,000 after acquiring an additional 2,000 shares during the last quarter. Finally, Envestnet Asset Management Inc. purchased a new position in shares of Biohaven Pharmaceutical during the 1st quarter worth $200,000. Institutional investors and hedge funds own 84.86% of the company’s stock.

In other news, Director Declan Doogan sold 40,000 shares of Biohaven Pharmaceutical stock in a transaction on Wednesday, February 13th. The shares were sold at an average price of $44.31, for a total transaction of $1,772,400.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider John Tilton sold 10,000 shares of Biohaven Pharmaceutical stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $50.11, for a total transaction of $501,100.00. Following the transaction, the insider now owns 10,000 shares in the company, valued at approximately $501,100. The disclosure for this sale can be found here. Insiders have sold a total of 437,856 shares of company stock worth $22,279,475 in the last quarter. Corporate insiders own 23.90% of the company’s stock.

About Biohaven Pharmaceutical

Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops late-stage products candidates targeting neurological diseases in the United States. Its clinical stage products include Rimegepant, a product that has completed phase III trials and is in long-term safety ongoing process for acute treatment and prevention of migraine; BHV-3500 that has completed phase I clinical trial for acute treatment and prevention of migraine; and Troriluzole that has completed II/III randomization phase and is ongoing extension trial for ataxias.

Featured Story: The mechanics of the bid-ask spread in trading

Earnings History and Estimates for Biohaven Pharmaceutical (NYSE:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.